EyeGate Pharmaceuticals, Inc.

    Jurisdiction
    United States
    ISIN
    US30233M5031 (EYEG)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €13.73M
    Gross margin
    -0.1%
    EBIT
    €673.89K
    EBIT margin
    4.9%
    Net income
    €7.35M
    Net margin
    53.5%

    Statement period: - (published )

    Dividends

    Last dividend amount
    $0.14
    Ex date
    Payment date

    Add to watchlist

    Notifications